Indické farmaceutické spoločnosti si môžu udržať dominantný podiel na trhu v USA pri predaji generických liekov, aj keď prezident Donald Trump zavedie clá, pretože sú „vysoko konkurencieschopné“. Uviedla to v
Indian pharmaceutical companies maintain a dominant position in the U.S. market, particularly in the sale of generic drugs, despite potential tariffs proposed by Donald Trump. These companies, including Sun Pharma, Dr. Reddy's, Cipla, and Zydus, are cost-effective and supported by organizations like Pharmexcil. Their exports to the U.S. contribute significantly, with revenues reaching around $9 billion. While tariffs could reduce profit margins, they emphasize their competitiveness. Generic drugs saved the U.S. healthcare system approximately $408 billion in 2022.
